Breaking News, Collaborations & Alliances

Eisai Enters Joint Research Alliance to Create SLE Treatment

Aims to create a Japan-originated therapeutic drug for systemic lupus erythematosus using Eisai’s new oral Toll-Like Receptor 7/8 inhibitor E6742.

By: Contract Pharma

Contract Pharma Staff

Eisai Co., Ltd. has entered into an industry-academia-government joint research agreement with four universities in Japan concerning the “Industrialization of Japan-originated Toll-like receptor research by Academia-Industry collaborating All-Japan system: Creation of new drug for SLE treatment”, a research project with Eisai as the representative research organization. In this project, Eisai aims to create a Japan-originated therapeutic drug for systemic lupus erythematosus (SLE) th...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters